Navigation

ExploreAnalysisInvestor RelationsAI AssistantCompareScreener
LoginSign Up FreeSign Up

© 2026 MarketCI. All rights reserved.

HelpPricingPrivacyTerms
CP

CPRX

Market Closed

Catalyst Pharmaceuticals, Inc.

NASDAQHealthcareBiotechnology
US
182 employees
CEO: Richard John Daly
Founded: 2006
$31.49
+$0.00(+NaN%)
Market Cap
3.85B
Beta
0.74
52W Range
N/A
Dividend Yield
0.00%
OverviewForecastsFundamentalMarket SentimentValuationOwnership
OverviewForecastsFundamentalMarket SentimentValuationOwnership
Comprehensive Valuation
In-depth valuation analysis including DCF scenarios and peer comparisons.
AI Insight: Based on PERT weighted analysis (confidence: high), the fair value is $84.47, implying 168.2% upside from current levels. The stock appears significantly undervalued. Financial health scores indicate strong fundamentals (4.4/5). Monte Carlo analysis shows low downside risk (0% of scenarios below current price). Overall, this suggests a compelling buying opportunity at current prices.
Enhanced Football Field Analysis
Loading comprehensive valuation data...

Fetching multi-methodology valuation ranges...

Explore CPRX

Overview

Key metrics and AI-powered insights

Forecast

Price targets and earnings estimates

Fundamentals

Income, balance sheet and cash flow

Valuation

P/E, DCF and valuation multiples

Ownership

Institutional and insider holdings

Sentiment

Analyst ratings and news sentiment

CPRX in the Healthcare

Mid Cap
Healthcare

Browse sector stocks →

Biotechnology

Browse industry stocks →